Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Amazon Debuts “Amazon Now” for 30-Minute Ultrafast Grocery Delivery 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
